Anzeige
Mehr »
Donnerstag, 13.08.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CT5N | ISIN: SE0015988274 | Ticker-Symbol: 5KC
Frankfurt
13.08.26 | 09:55
0,108 Euro
-1,38 % -0,002
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PILA PHARMA AB Chart 1 Jahr
5-Tage-Chart
PILA PHARMA AB 5-Tage-Chart

Aktueller Chart PILA PHARMA Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
PILA PHARMA AB-Investoren interessieren sich auch für diese Wertpapiere
Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated...
► Artikel lesen
Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria...
► Artikel lesen
Cogent Biosciences, Inc.: Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145...
► Artikel lesen
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients...
► Artikel lesen
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal DevelopmentTreatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up...
► Artikel lesen
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated...
► Artikel lesen
New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical ResultsSponsored Programming Also Broadcasts Across Bloomberg Television in Latin America and MENA, Expanding the Global Reach of New to The Street's Featured Companies NEW YORK CITY, NY / ACCESS Newswire...
► Artikel lesen
RedChip Companies, Inc.: Join Biovie's Exclusive Live Investor Webinar: Inside the SUNRISE-PD Topline ResultsBioVie CEO Cuong Do to discuss the newly released Phase 2 SUNRISE-PD results and what they mean for the future development of bezisterim in Parkinson's diseaseLearn how the BioVie's differentiated approach...
► Artikel lesen
BioVie, Inc.: BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's DiseasePatients treated with bezisterim demonstrated statistically significant improvements compared to placebo on both motor and non-motor symptoms, as assessed by MDS-UPDRS1 Parts I, II, and III, as well...
► Artikel lesen